61 – 70 of 85
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
How much is too much?- Defining the Metes and Bounds of Excessive Pricing in the Pharmaceutical Sector
(
- Contribution to journal › Article
-
Mark
Will the EPO’s Enlarged Board of Appeal hear the Broad's CRISPR case?
2018) In Life Sciences Intellectual Property Review (LSIPR)(
- Contribution to journal › Article
-
Mark
Big Data in the Health and Life Sciences: What Are the Challenges for European Competition Law and Where Can They Be Found?
2018) In CEIPI / ICTSD Publication Series on Global Perspectives and Challenges for the Intellectual Property System p.121-130(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2017
-
Mark
The Rights of Children in Biomedicine : Challenges posed by scientific advances and uncertainties
2017)(
- Book/Report › Report
- 2016
-
Mark
Lost in Translation: Interpretation of Legal Capacity in Ukraine
(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2015
-
Mark
Ārstniecība cilvēka dzīves nogalē un nāves tiesiskie aspekti
2015) p.639-675(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Medicīnas tiesības
Slokenberga, Santa LU (2015)
- Book/Report › Anthology (editor)
-
Mark
Will clinical trial data disclosure reduce incentives to develop new uses of drugs?
(
- Contribution to journal › Article
-
Mark
IPRs in Biobanking: Risks and Opportunities for Translational Research
(
- Contribution to journal › Article
-
Mark
A “ray of hope” for European stem cell patents or “out of the smog into the fog”?: The CJEU decision in C-364/13 and how it compares to recent US developments.(under review)
2015) In Biotechnology Law Report(
- Contribution to journal › Article